• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

心脏辅助装置 HeartWare 患者停用抗凝或抗血小板治疗 5 天并使用诺和诺德 NovoSeven。

Five days of no anticoagulation or antiplatelet therapy and NovoSeven administration in a HeartWare HVAD patient.

机构信息

Clinics for Cardiovascular Surgery Cardiology, Pneumology and Angiology, Heinrich-Heine University of Düsseldorf, Moorenstrasse 5, Düsseldorf, Germany.

出版信息

Artif Organs. 2012 Aug;36(8):751-3. doi: 10.1111/j.1525-1594.2012.01473.x. Epub 2012 May 20.

DOI:10.1111/j.1525-1594.2012.01473.x
PMID:22607278
Abstract

Postoperative bleeding is the most common complication following the implantation of ventricular assist devices. This is a case report of a HeartWare HVAD patient with intractable bleeding following chest tube insertion necessitating massive blood transfusion and multiple thoracotomies. Anticoagulation and antiplatelet therapy were discontinued and intravenous NovoSeven was administered as last resort. Bleeding ceased immediately and no pump-related issues were observed. However, thrombus formation in the right atrium and superior vena cava was detected.

摘要

术后出血是心室辅助装置植入后最常见的并发症。这是一例 HeartWare HVAD 患者的病例报告,该患者在插入胸腔引流管后出现难治性出血,需要大量输血和多次开胸手术。停止抗凝和抗血小板治疗,并作为最后手段给予静脉注射诺其。出血立即停止,未观察到与泵相关的问题。然而,检测到右心房和上腔静脉形成血栓。

相似文献

1
Five days of no anticoagulation or antiplatelet therapy and NovoSeven administration in a HeartWare HVAD patient.心脏辅助装置 HeartWare 患者停用抗凝或抗血小板治疗 5 天并使用诺和诺德 NovoSeven。
Artif Organs. 2012 Aug;36(8):751-3. doi: 10.1111/j.1525-1594.2012.01473.x. Epub 2012 May 20.
2
[Successful use of recombinant factor VIIa in the control of a massive bleeding in two patients with biventricular assist device (Thoratec)].[重组凝血因子VIIa成功用于控制两名使用双心室辅助装置(Thoratec)患者的大出血]
Ann Fr Anesth Reanim. 2010 Jan;29(1):45-7. doi: 10.1016/j.annfar.2009.10.017. Epub 2010 Jan 18.
3
The danger of using a sledgehammer to crack a nut: ROTEM-guided administration of recombinant activated factor VII in a patient with refractory bleeding post-ventricular assist device implantation.用大锤砸坚果的危险:旋转血栓弹力图(ROTEM)指导下对一名心室辅助装置植入术后难治性出血患者使用重组活化凝血因子VII。
Artif Organs. 2015 Mar;39(3):248-53. doi: 10.1111/aor.12355. Epub 2014 Jul 28.
4
An analysis of pump thrombus events in patients in the HeartWare ADVANCE bridge to transplant and continued access protocol trial.对 HeartWare ADVANCE 桥接移植和持续准入方案试验中患者的泵血栓事件进行分析。
J Heart Lung Transplant. 2014 Jan;33(1):23-34. doi: 10.1016/j.healun.2013.12.001. Epub 2013 Dec 12.
5
Ambient hemolysis and activation of coagulation is different between HeartMate II and HeartWare left ventricular assist devices.环境性溶血和凝血激活在 HeartMate II 和 HeartWare 左心室辅助装置之间存在差异。
J Heart Lung Transplant. 2014 Jan;33(1):80-7. doi: 10.1016/j.healun.2013.11.010. Epub 2013 Dec 1.
6
Gastrointestinal bleeding in recipients of the HeartWare Ventricular Assist System.哈特外尔心室辅助系统治疗患者的胃肠道出血。
JACC Heart Fail. 2015 Apr;3(4):303-13. doi: 10.1016/j.jchf.2014.11.008. Epub 2015 Mar 11.
7
Assessing Anticoagulation Practice Patterns in Patients on Durable Mechanical Circulatory Support Devices: An International Survey.
ASAIO J. 2016 Jan-Feb;62(1):28-32. doi: 10.1097/MAT.0000000000000274.
8
Primary anticoagulation with bivalirudin for patients with implantable ventricular assist devices.使用比伐卢定对植入式心室辅助装置患者进行初始抗凝治疗。
Artif Organs. 2014 Apr;38(4):342-6. doi: 10.1111/aor.12168. Epub 2013 Sep 19.
9
The use of eptifibatide for suspected pump thrombus or thrombosis in patients with left ventricular assist devices.依替巴肽在左心室辅助装置患者疑似泵血栓或血栓形成中的应用。
J Heart Lung Transplant. 2014 Jan;33(1):94-101. doi: 10.1016/j.healun.2013.11.002. Epub 2013 Nov 25.
10
rFVIIa in the treatment of persistent hemorrhage in pediatric patients on ECMO following surgery for congenital heart disease.重组活化凝血因子VII(rFVIIa)用于治疗先天性心脏病手术后接受体外膜肺氧合(ECMO)的儿科患者的持续性出血。
Paediatr Anaesth. 2007 Dec;17(12):1176-81. doi: 10.1111/j.1460-9592.2007.02328.x.